Seres Therapeutics Ownership | Who Owns Seres Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Seres Therapeutics Ownership Summary


Seres Therapeutics is owned by 3.81% institutional investors, 12.44% insiders, and 83.75% retail investors. Flagship pioneering is the largest institutional shareholder, holding 13.22% of MCRB shares. Fidelity Growth Compy Commingled Pl O is the top mutual fund, with 5.55% of its assets in Seres Therapeutics shares.

MCRB Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSeres Therapeutics3.81%12.44%83.75%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Flagship pioneering1.16M13.22%$22.24M
Vanguard group324.21K3.70%$4.82M
Marshall wace, llp125.60K1.44%$2.42M
Blackrock1.76M1.21%$1.28M
Blackrock funding, inc. /de103.62K1.18%$1.54M
Vontobel103.23K1.18%$1.54M
Geode capital management86.14K0.98%$1.28M
Charles schwab investment management31.40K0.36%$604.19K
State street29.73K0.34%$572.02K
Schonfeld strategic advisors28.94K0.33%$556.84K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Flagship pioneering1.16M7.60%$22.24M
Lion point capital, lp27.14K2.97%$522.13K
J. goldman & co lp27.00K0.01%$519.48K
Vontobel103.23K0.00%$1.54M
Schonfeld strategic advisors28.94K0.00%$556.84K
Marshall wace, llp125.60K0.00%$2.42M
Sbi securities3.48K0.00%$51.81K
Physician wealth advisors142.000.00%$2.11K
Charles schwab investment management31.40K0.00%$604.19K
Geode capital management86.14K0.00%$1.28M

Top Buyers

HolderShares% AssetsChange
Marshall wace, llp125.60K0.00%34.20K
Schonfeld strategic advisors28.94K0.00%28.94K
J. goldman & co lp27.00K0.01%27.00K
Goldman sachs group14.34K-14.34K
Vanguard group324.21K0.00%12.32K

Top Sellers

HolderShares% AssetsChange
Blackrock1.76M--5.06M
Woodline partners lp---2.05M
Millennium management29.55K--1.78M
Bank of america corp /de/105.04K--1.55M
Handelsbanken fonder ab---1.10M

New Positions

HolderShares% AssetsChangeValue
Schonfeld strategic advisors28.94K0.00%28.94K$556.84K
J. goldman & co lp27.00K0.01%27.00K$519.48K
Goldman sachs group14.34K-14.34K$213.38K
Invesco10.44K-10.44K$200.90K
Macquarie group4.95K-4.95K$3.58K

Sold Out

HolderChange
Whittier trust-1.00
Federation des caisses desjardins du quebec-3.00
Headlands-10.00
Us bancorp \de\-12.00
Point72 (difc)-17.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 20257-84.09%333,553-84.31%30.64%3-88.46%1-85.71%
Sep 30, 202510-71.43%448,121-80.32%50.76%5-54.55%1-95.45%
Jun 30, 202536-44.62%2,284,946-96.28%262.10%13-35.00%2116.67%
Mar 31, 20253-96.00%23,487,356-62.76%130.79%--100.00%1-94.44%
Dec 31, 202470-13.58%62,481,139-1.44%402.37%25-3.85%17-34.62%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl O9.44M5.55%92.60K
Vanguard US Total Market Shares ETF4.04M2.32%-
Vanguard Total Stock Mkt Idx Inv206.17K2.28%-
Fidelity Growth Compy Commingled Pl S108.78K1.25%-73.89K
Vanguard Institutional Extnd Mkt Idx Tr69.95K0.77%-
Vanguard Explorer Inv1.22M0.72%-
Avantis US Small Cap Value ETF56.03K0.62%-
Fidelity Select Biotechnology854.35K0.50%-
Fidelity Series Growth Company38.18K0.44%-22.70K
LUX IM Global Medtech HX38.13K0.42%38.13K

Recent Insider Transactions


DateNameRoleActivityValue
Feb 15, 2026Shaff Eric D.-Sell$2.19K
Feb 15, 2026Young Teresa L. See RemarksSell$635.25
Feb 15, 2026DesRosier Thomas See RemarksSell$660.66
Feb 15, 2026Henn Matthew R See RemarksSell$753.83
Nov 15, 2025Young Teresa L. See RemarksSell$18.03K

Insider Transactions Trends


DateBuySell
2026 Q1-4
2025 Q4-4
2025 Q3-4
2025 Q2-4
2025 Q1-5

MCRB Ownership FAQ


Who Owns Seres Therapeutics?

Seres Therapeutics shareholders are primarily institutional investors at 3.81%, followed by 12.44% insiders and 83.75% retail investors. The average institutional ownership in Seres Therapeutics's industry, Biotech Stocks , is 381.47%, which Seres Therapeutics falls below.

Who owns the most shares of Seres Therapeutics?

Seres Therapeutics’s largest shareholders are Flagship pioneering (1.16M shares, 13.22%), Vanguard group (324.21K shares, 3.70%), and Marshall wace, llp (125.6K shares, 1.44%). Together, they hold 18.36% of Seres Therapeutics’s total shares outstanding.

Does Blackrock own Seres Therapeutics?

Yes, BlackRock owns 1.21% of Seres Therapeutics, totaling 1.76M shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 1.28M$. In the last quarter, BlackRock decreased its holdings by -5.063M shares, a -74.18% change.

Who is Seres Therapeutics’s biggest shareholder by percentage of total assets invested?

Flagship pioneering is Seres Therapeutics’s biggest shareholder by percentage of total assets invested, with 7.60% of its assets in 1.16M Seres Therapeutics shares, valued at 22.24M$.

Who is the top mutual fund holder of Seres Therapeutics shares?

Fidelity Growth Compy Commingled Pl O is the top mutual fund holder of Seres Therapeutics shares, with 5.55% of its total shares outstanding invested in 9.44M Seres Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools